Role of substrate stiffness in the treatment of malignant tumor

Abstract

Abstract:

Substrate stiffness is one of the important mechanical parameters of extracellular matrix. Different substrate stiffness will affect the proliferation, movement and phenotype of tumor cells. It is found that the change of substrate stiffness is also related to the chemotherapy and radiotherapy sensitivity of tumor cells. Substrate stiffness can cause changes in the characteristics of tumor stem cells, which are related to the activation or inactivation of some signaling pathways, mainly involving ABCG2 protein and Akt/mTOR/Sox2 signaling pathway. Further study on the role of substrate stiffness in radiotherapy, chemotherapy and targeted therapy of malignant tumor is expected to provide basis for the clinical treatment of malignant tumor.

Key words:Neoplasms,Chemoradiotherapy,Molecular targeted therapy,Substrate stiffness

Deng Bo'er, Kong Weimin. Role of substrate stiffness in the treatment of malignant tumor[J]. Journal of International Oncology, 2021, 48(9): 557-559.

References24

[1]	Darnell M, Gu L, Mooney D. RNA-seq reveals diverse effects of substrate stiffness on mesenchymal stem cells[J]. Biomaterials, 2018, 181:182-188. DOI: 10.1016/j.biomaterials.2018.07.039. doi:S0142-9612(18)30524-6pmid:30086447
[2]	Fiejdasz S, Horak W, Lewandowska-Łańcucka J, et al. Tuning of elasticity and surface properties of hydrogel cell culture substrates by simple chemical approach[J]. J Colloid Interface Sci, 2018, 524:102-113. DOI: 10.1016/j.jcis.2018.04.004. doi:10.1016/j.jcis.2018.04.004
[3]	Jiang T, Zhao J, Yu S, et al. Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels[J]. Biomaterials, 2019, 188:130-143. DOI: 10.1016/j.biomaterials.2018.10.015. doi:10.1016/j.biomaterials.2018.10.015
[4]	Eble JA, Niland S. The extracellular matrix in tumor progression and metastasis[J]. Clin Exp Metastasis, 2019, 36(3):171-198. DOI: 10.1007/s10585-019-09966-1. doi:10.1007/s10585-019-09966-1
[5]	Munoz A, Eldridge WJ, Jakobsen NM, et al. Corrigendum: cellular shear stiffness reflects progression of arsenic-induced transformation during G₁[J]. Carcinogenesis, 2019, 40(10):1298. DOI: 10.1093/carcin/bgz048. doi:10.1093/carcin/bgz048
[6]	Shukla VC, Higuita-Castro N, Nana-Sinkam P, et al. Substrate stiffness modulates lung cancer cell migration but not epithelial to mesenchymal transition[J]. J Biomed Mater Res A, 2016, 104(5):1182-1193. DOI: 10.1002/jbm.a.35655. doi:10.1002/jbm.a.35655pmid:26779779
[7]	Qin X, Lv X, Li P, et al. Matrix stiffness modulates ILK-mediated YAP activation to control the drug resistance of breast cancer cells[J]. Biochim Biophys Acta Mol Basis Dis, 2020, 1866(3):165625. DOI: 10.1016/j.bbadis.2019.165625. doi:10.1016/j.bbadis.2019.165625
[8]	焦思萌, 赵轩宇, 宋丹, 等. 基底刚度对人宫颈癌HeLa细胞增殖及顺铂药物敏感性影响的体外研究[J]. 癌症进展, 2019, 17(22):2642-2644, 2651. DOI: 10.11877/j.issn.1672-1535.2019.17.22.09. doi:10.11877/j.issn.1672-1535.2019.17.22.09
[9]	Wang W, Lollis EM, Bordeleau F, et al. Matrix stiffness regulates vascular integrity through focal adhesion kinase activity[J]. FASEB J, 2019, 33(1):1199-1208. DOI: 10.1096/fj.201800841R. doi:10.1096/fj.201800841R
[10]	Chae YC, Kim JH. Cancer stem cell metabolism: target for cancer therapy[J]. BMB Rep, 2018, 51(7):319-326. DOI: 10.5483/bmbrep.2018.51.7.112. doi:10.5483/bmbrep.2018.51.7.112
[11]	Chen Z, Zhu P, Zhang Y, et al. Enhanced sensitivity of cancer stem cells to chemotherapy using functionalized mesoporous silica nanoparticles[J]. Mol Pharm, 2016, 13(8):2749-2759. DOI: 10.1021/acs.molpharmaceut.6b00352. doi:10.1021/acs.molpharmaceut.6b00352
[12]	Wang Y, Jiang F, Jiao K, et al. De-methylation of miR-148a by arsenic trioxide enhances sensitivity to chemotherapy via inhibiting the NF-κB pathway and CSC like properties[J]. Exp Cell Res, 2020, 386(2):111739. DOI: 10.1016/j.yexcr.2019.111739. doi:10.1016/j.yexcr.2019.111739
[13]	Hu J, Li J, Yue X, et al. Targeting BCRP/ABCG2 by RNA interference enhances the chemotherapy sensitivity of human colon cancer side population cells[J]. J Huazhong Univ Sci Technolog Med Sci, 2017, 37(2):231-236. DOI: 10.1007/s11596-017-1720-1. doi:10.1007/s11596-017-1720-1
[14]	Hui L, Zhang J, Ding X, et al. Matrix stiffness regulates the proli-feration, stemness and chemoresistance of laryngeal squamous cancer cells[J]. Int J Oncol, 2017, 50(4):1439-1447. DOI: 10.3892/ijo.2017.3877. doi:10.3892/ijo.2017.3877
[15]	Amawi H, Sim HM, Tiwari AK, et al. ABC transporter-mediated multidrug-resistant cancer[J]. Adv Exp Med Biol, 2019, 1141:549-580. DOI: 10.1007/978-981-13-7647-4_12. doi:10.1007/978-981-13-7647-4_12
[16]	Robey RW, Pluchino KM, Hall MD, et al. Revisiting the role of ABC transporters in multidrug-resistant cancer[J]. Nat Rev Cancer, 2018, 18(7):452-464. DOI: 10.1038/s41568-018-0005-8. doi:10.1038/s41568-018-0005-8
[17]	Sicchieri RD, da Silveira WA, Mandarano LR, et al. ABCG2 is a potential marker of tumor-initiating cells in breast cancer[J]. Tumour Biol, 2015, 36(12):9233-9243. DOI: 10.1007/s13277-015-3647-0. doi:10.1007/s13277-015-3647-0
[18]	You Y, Zheng Q, Dong Y, et al. Matrix stiffness-mediated effects on stemness characteristics occurring in HCC cells[J]. Oncotarget, 2016, 7(22):32221-32231. DOI: 10.18632/oncotarget.8515. doi:10.18632/oncotarget.8515
[19]	De Ruysscher D, Niedermann G, Burnet NG, et al. Radiotherapy toxicity[J]. Nat Rev Dis Primers, 2019, 5(1):13. DOI: 10.1038/s41572-019-0064-5. doi:10.1038/s41572-019-0064-5pmid:30792503
[20]	Cree A, O'Donovan A, O'Hanlon S. New horizons in radiotherapy for older people[J]. Age Ageing, 2019, 48(5):605-612. DOI: 10.1093/ageing/afz089. doi:10.1093/ageing/afz089
[21]	Panzetta V, Verde G, Pugliese M, et al. Adhesion and migration response to radiation therapy of mammary epithelial and adenocarcinoma cells interacting with different stiffness substrates[J]. Cancers (Basel), 2020, 12(5):1170. DOI: 10.3390/cancers12051170. doi:10.3390/cancers12051170
[22]	Lacombe J, Harris AF, Zenhausern R, et al. Plant-based scaffolds modify cellular response to drug and radiation exposure compared to standard cell culture models[J]. Front Bioeng Biotechnol, 2020, 8:932. DOI: 10.3389/fbioe.2020.00932. doi:10.3389/fbioe.2020.00932
[23]	Bruix J, Qin S, Merle P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064):56-66. DOI: 10.1016/S0140-6736(16)32453-9. doi:10.1016/S0140-6736(16)32453-9
[24]	Gao J, Rong Y, Huang Y, et al. Cirrhotic stiffness affects the migration of hepatocellular carcinoma cells and induces sorafenib resis-tance through YAP[J]. J Cell Physiol, 2019, 234(3):2639-2648. DOI: 10.1002/jcp.27078. doi:10.1002/jcp.27078